Abstract:Background Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. Methods Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records database covering visits to public healthcare providers for 3% of the Spanish population. Patients with a migraine diagnosis (ICD-9 346) between 01/2015 and 04/2022 were included, as well as their demographic and clinical characteristics, prescribed migraine treatments and the specialty of the prescribing physicians. Results The database included 61,204 patients diagnosed with migraine. A migraine treatment had been prescribed to 50.6% of patients over the last 24 months (only acute to 69.5%, both acute and preventive to 24.2%, and only preventive to 6.3%). The most frequently prescribed treatments were NSAIDs (56.3%), triptans (44.1%) and analgesics (28.9%). Antidepressants were the most common preventive treatment (prescribed to 17.9% of all treated patients and 58.7% of those treated with a preventive medication), and anti-CGRP monoclonal antibodies the least prescribed (1.7%; 5.7%). In 13.4% of cases, preventive medications were the first treatment: alone in 5.8% of cases and together with an acute medication in 7.6%. A fifth of patients who were initially prescribed with only acute treatment were later prescribed a preventive medication (20.7%). On average, it took 29.4 months for this change to occur. Two-thirds of patients started their preventive treatment in primary care (64.2%). The percentage of patients treated by a neurologist increased with the number of received preventive medications. However, 28.8% of patients who had already been prescribed five or more distinct preventive treatments were not treated by a neurologist. Migraine patients had between 1.2- and 2.2-times higher prevalence of comorbidities than the general population, age-gender adjusted. Conclusions Our study emphasizes the need for improved management of migraine in Spain to reduce the risk of chronification and improve patient outcomes. More training and coordination across healthcare professionals is necessary to recognize and address risk factors for migraine progression, including multiple associated comorbidities and several lines of treatment, and to provide personalized treatment plans that address the complex nature of the condition.

Resistant and refractory migraine – two different entities with different comorbidities? Results from the REFINE study

European headache federation consensus on the definition of resistant and refractory migraine

Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications

Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life

Hallmarks of primary headache: part 1 – migraine

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients

Somatosensory and psychosocial profile of migraine patients: A cross-sectional study

Insights into Chronic Migraine and Medication Overuse Headache with Electrophysiological Analysis

Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Pre- and post-headache phases of migraine: multi-country results from the CaMEO - International Study

Depression comorbidity in migraine

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Migraine Comorbidities

Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives

Migraine-associated risks and comorbidity

Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study

Migraine Treatment: Towards New Pharmacological Targets

Functional Neuroimaging Biomarkers in Migraine: Diagnostic, Prognostic and Therapeutic Implications

Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel